Ozempic vs Mounjaro: Which Actually Works Better?

If you’ve spent any time researching GLP-1 compounds, you’ve hit the same wall everyone does: Ozempic and Mounjaro get talked about like rivals, but half the internet can’t agree on what actually separates them. Here’s the part most pages bury — they aren’t two flavours of the same drug. They’re built on two different molecules that reach your metabolism through a different number of doors, and that single fact drives almost everything else, from how much weight comes off in trials to how your stomach feels in week one.

This is a research-focused breakdown of semaglutide (Ozempic/Wegovy) versus tirzepatide (Mounjaro/Zepbound) — the mechanisms, the head-to-head trial data, and the honest trade-offs. No hype, no protocols.

Brand names vs the actual molecules

The naming is where most confusion starts, so clear it first. Ozempic and Wegovy are the same molecule — semaglutide — sold under two brands (Ozempic for type 2 diabetes, Wegovy for weight management). Mounjaro and Zepbound are also the same molecule — tirzepatide — split the same way. So “Ozempic vs Mounjaro” is really semaglutide vs tirzepatide wearing marketing jackets. Once you think in molecules instead of brands, the comparison stops being a popularity contest and becomes a question of pharmacology.

For a wider map of every compound in this space, start with our GLP-1 weight loss drugs guide, then come back here for the direct duel.

One receptor vs two

Semaglutide is a single agonist: it mimics GLP-1, a gut hormone your body releases after eating that tells your brain you’re full, slows how fast your stomach empties, and sharpens insulin response. Tirzepatide is a dual agonist: it hits the GLP-1 receptor and the GIP receptor, a second incretin hormone. The working theory is that adding GIP amplifies the appetite and metabolic effects beyond what GLP-1 does alone — and the trial numbers below are the clearest argument that the second door matters.

Weight loss, head-to-head

This is the heading everyone scrolls to, so here’s the data straight. In its pivotal weight-management trial (STEP-1), semaglutide produced roughly 14.9% mean body-weight reduction over 68 weeks (Wilding et al., NEJM 2021). Tirzepatide’s pivotal trial (SURMOUNT-1) reported up to ~21% over 72 weeks (Jastreboff et al., NEJM 2022, PMID 35658024). But the cleanest answer came when the two were put in the same trial: SURMOUNT-5 pitted them directly and tirzepatide delivered 20.2% vs semaglutide’s 13.7% (NEJM 2025). In diabetes, SURPASS-2 told the same story — tirzepatide beat semaglutide on both weight and blood-sugar control.

In the only trial that tested them side by side, tirzepatide reached 20.2% weight reduction versus 13.7% for semaglutide — a gap too large to explain away as noise.SURMOUNT-5, NEJM 2025

Side effects compared

Both compounds share the same dominant side-effect profile, and it comes straight from the mechanism: because they slow gastric emptying, the most common complaints are gastrointestinal — nausea, vomiting, diarrhea, constipation. These are dose-dependent and tend to fade as the body adjusts, which is exactly why clinical protocols titrate upward slowly rather than starting high. The rare-but-serious signals studied across the class include gallstones, pancreatitis, and gastroparesis, plus a boxed warning for thyroid C-cell tumors derived from rodent studies (contraindicated in people with a history of medullary thyroid carcinoma or MEN2). Head-to-head, tirzepatide’s GI profile has looked broadly comparable to semaglutide’s despite its larger effect — but “comparable” is not “none.”

So which is “better”?

If the only axis is weight reduction, the data points one direction: tirzepatide. The dual GIP/GLP-1 mechanism keeps winning direct comparisons, and it’s the reason the newest triple-agonist, retatrutide, is generating so much interest — it adds a third receptor on top. If the axis is “longest real-world history and cardiovascular-outcome evidence,” semaglutide still holds that ground. For research buyers comparing reference material, tirzepatide is the more potent benchmark; semaglutide is the more studied one.

Researchers sourcing a tirzepatide reference compound can review our TZ-2 (tirzepatide) listing, and those tracking the next generation should read retatrutide vs tirzepatide for where the field is heading.

FAQ